Our Firm continues to hear from Lipitor patients on a fairly regular basis who claim they developed Type 2 diabetes due to their use of this medication. It is not at all surprising that the litigation continues to grow at a relatively quick pace.
New York, New York (PRWEB) October 27, 2014
The number of Lipitor lawsuits (http://www.lipitorlawsuitcenter.com/) that allege the statin medication increases the risk for new-onset Type 2 diabetes continues to mount in the federal multidistrict litigation currently underway in U.S. District Court, District of South Carolina, Bernstein Liebhard LLP reports. According to an updated Docket Report issued by the U.S. Judicial Panel on Multidistrict Litigation (JPML) on October 15, 2014, at least 1,355 claims are now pending in the proceeding. That represents an increase of 85 filings since the JPML issued a previous update on September 15th, at which time 1,270 cases were pending. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
“Our Firm continues to hear from Lipitor patients on a fairly regular basis who claim they developed Type 2 diabetes due to their use of this medication. It is not at all surprising that the litigation continues to grow at a relatively quick pace,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential case reviews to individuals who may have been harmed by Lipitor.
Lipitor Diabetes Allegations
According to court documents, the Lipitor diabetes litigation has been growing since February 2012, when the U.S. Food & Drug Administration (FDA) ordered the manufacturers of statin drugs to include information on their labels regarding a possible association between their use and Type 2 diabetes. The FDA acted after a study published in JAMA: Internal Medicine indicated that women using the medications may be at an increased risk of developing the disease.*
Plaintiffs who have filed Lipitor lawsuits pending in the federal litigation accuse Pfizer, Inc. being aware of the association between the medication and diabetes, and of concealing this knowledge from doctors and patients. They also allege that that the label modification instituted by Pfizer to comply with the FDA’s 2012 directive was inadequate, and still does not sufficiently warn Lipitor users that they may be at increased risk for Type 2 diabetes.
Lipitor patients who allegedly developed Type 2 diabetes due to the statin medication may be entitled to bring their own claim against Pfizer. To learn more about filing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to obtain a free legal review.
*archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com